myosin

Myosin V-IN-1 is a potent and selective inhibitor of Myosin V with a Ki value of 6 μM.Myosin V-IN-1 inhibits actin V and slows down actin-activated myosin V ATPase by selectively inhibiting the release of ADP from the actinoglobulin complex.

ATM-3507 is a protomyosin inhibitor with anticancer activity that inhibits human melanoma and can be used to study ovarian cancer.

MS-444 (BE-34776) is a smooth muscle myosin light chain kinase (MLCK) and HuR inhibitor with antitumor activity for triple-negative breast and colorectal cancer.

Mavacamten (MYK-461) is an orally bioavailable inhibitor of cardiac myosin ATPase,( IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively)

Danicamtiv (MYK-491) is an inotropic agent and it also is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency.

ML-9 suppresses MLCK, PKA, and PKC activity with Ki values of 4, 32, and 54 μM, respectively. ML-9 is a selective and effective inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK), and stromal interaction molecule 1 (STIM1) activity. ML-9 causes autophagy by stimulating autophagosome formation and inhibiting their degradation.

Omecamtiv mecarbil (CK-1827452) has been used in trials studying the treatment and basic science of Heart Failure, Echocardiogram, Pharmacokinetics, Chronic Heart Failure, and History of Chronic Heart Failure, among others.

W-7 hydrochloride (W-7 HCl), a calmodulin antagonist, inhibits Ca2+-calmodulin-dependent myosin light chain kinase and phosphodiesterase, W-7 hydrochloride induces apoptosis and has antitumor activity.

Blebbistatin ((±)-Blebbistatin) is a non-muscle myosin II (NMII)-selective and non-muscle myosin heavy chain 9 (MYH9)-specific inhibitor that promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, while preserving the integrity of cell junctions and barrier function.

2,3-Butanedione 2-Monoxime (Diacetyl monoxime) is an inhibitor of skeletal and cardiac muscle contraction.

Phenamacril (JS39919) is acyanoacrylate fungicide, has powerful inhibition against Fusarium species, especially to Fusarium graminearum. Phenamacril is a specific Fusarium myosin I inhibitor.

Pentachloropseudilin (PClP) is a reversible variant 1 myosin inhibitor with antimicrobial activity that inhibits Myo1s and class 5 myosins.Pentachloropseudilin inhibits growth factor-beta (TGF-β), which blocks host cell invasion by Trypanosoma cruzi.

ML-7 hydrochloride (ML-7 HCl) is a cell-permeable, reversible, effective, ATP-competitive, and specific inhibitor of myosin light chain kinase (Ki: 300 nM); also inhibits smooth-muscle myosin light chain kinase, PKA, and PKC.

(-)-Blebbistatin ((S)-(-)-Blebbistatin) is an S enantiomer of blebbistatin. It is a potent and selective myosin II inhibitor with IC50 ranging from 0.5 to 5 μM.

JB061 is a nonmuscle myosin inhibitor, demonstrating selective inhibitory activity with IC50 values of 4.4 μM (Cardiac muscle myosin), 9.1 μM (Skeletal muscle myosin), and >100 μM (Smooth muscle myosin II). It exhibits limited efficacy in reducing ATPase activity, with an IC50 exceeding 200 μM. Furthermore, JB061 displays cytotoxic effects on COS-7 cells, evidenced by an IC50 value of 39 μM.

JB062 is a chemical compound acting as a nonmuscle myosin inhibitor, exhibiting IC50 values of 1.6, 5.4, and >100 μM against skeletal muscle myosin, cardiac muscle myosin, and smooth muscle myosin II, respectively. It selectively exhibits cytotoxicity towards human cancer cells without affecting normal cells. The compound is applicable in research fields concerning muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.

JB002, a myosin II inhibitor, exhibits potent activity with an IC50 of ≤10 μM. It holds potential for research applications in muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.

HA-100 is an inhibitor of protein kinase

Aficamten is a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy.

Myosin-IN-1 (compound F10), a specific inhibitor of cardiac myosin, acts by stabilizing the cardiac myosin motor domain in its closed biochemical and structural state. It reduces myocardial force production and calcium sensitivity, functioning as a negative inotropic agent. In isolated Langendorff-perfused rat hearts, Myosin-IN-1 decreases stress in myofilaments and diminishes the development of left ventricular pressure. This compound is applicable in heart failure research [1].

Myosinmodulator 1 (Compound B141) is a myosin regulator that inhibits ATPase activity in rabbit psoas, porcine atrial, and porcine ventricular tissues, with IC25 values of 0.42, 0.13, and 3.09 μM, respectively. It also modulates cardiac contraction in Sprague Dawley rats.

Myosinmodulator 2 (Compound B172) is a myosin modulator that can inhibit ATPase activity in rabbit psoas muscle, pig atrium, and pig ventricle with IC25 values of 2.013, 2.94, and 20.93 μM, respectively. Additionally, Myosinmodulator 2 influences cardiac contractility in Sprague Dawley rats.

MyosinH Chain Fragment, mouse is a fragment derived from the α-myosin heavy chain peptide and can be used to induce experimental autoimmune myocarditis (EAM) in mouse models.

Myosin H Chain Fragment, mouse acetate salt is a peptide segment derived from the α-myosin heavy chain and is used to induce experimental autoimmune myocarditis (EAM) in mice.